Myobloc Articles
US FDA opens safety review on Botox
18 February 2008
Solstice raises $85M in private financing
13 November 2006
Allergan 3rd-qtr sales lifted by Botox
15 November 2004
Elan gains $89.5M from Xcel investment
7 April 2003
Strong earnings growth for Ireland's Elan on healthy US sales
11 February 2002
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
Elan net income leaps 89% in 1st qtr
24 April 2001
Elan full-year 2000 sales top $1.50 billion
29 January 2001
Botox cleared for neck pain in USA
2 January 2001
First approval for Elan's Myobloc in USA - revised
14 December 2000
US approval for Elan's Myobloc
12 December 2000
Elan's NeuroBloc backed by CPMP
6 November 2000
Elan's 3rd-qtr product revenues soar 51%
20 October 2000
Eisai to market Elan's cervical dystonia drug
12 October 2000
Liposome and Segix boost Elan revenues
21 July 2000
Elan "on track" with key products
20 June 2000
Allergan launches Alocril in USA
2 March 2000
Elan posts strong first quarter sales growth
26 April 1999
NeuroBloc effective in cervical dystonia
21 April 1999
4th qtr revenues rise 96% at Elan
12 February 1999
Elan files PLA for NeuroBloc in USA
12 January 1999
Elan Completes Ziconotide Phase III In Neuropathic Pain
15 December 1998
Elan's Combi Nicotine Patch A Partial Success
24 November 1998
Revenues Rise 63% At Ireland's Elan Corp In Third Quarter
27 October 1998
Elan And Axogen: Ph III Neurobloc Data
23 April 1998
Showing 1-32 of 32 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
